Showing posts with label $99 Autosomal DNA Test. Show all posts
Showing posts with label $99 Autosomal DNA Test. Show all posts

Thursday, December 13, 2012

Seismic Shift in Genetic Genealogy



It seems like the entire landscape of genetic genealogy has shifted in the last week. What magnitude on the Richter Scale were the shakes that led to this amount of widespread and almost simultaneous change? Only time will tell as to which of theses events will have the most lasting impact.

First we had 23andMe upgrading their "Ancestry Painting" feature. That feature previously had been interesting enough for it to form the central analysis tool for Bryan Sykes to analyze a couple dozen American genomes and generate his recent travelog DNA USA: A Genetic Portrait of America. Now their upgrade to "Ancestry Composition" is much more interesting and informative. The company followed that up with a blockbuster announcement of a permanent reduction of their test to $99. 

Wedged in between these two events National Geographic and explorer in residence, Spencer Wells began to release the first results of their Genographic Project, Geno 2.0.

Then Family Tree DNA (FTDNA) unveiled a major upgrade to their website and their database that will cause all of us who have tested there to reassess our results. All the pieces of the revamped website are not fully funcioning yet but the results are extremely interesting: 
Previously only exact full mitochondrial matches were displayed. Now those within a couple of mutations can also be viewed. This is an extension of similar latitude previously shown in displaying results on partial mitochondrial results.

Y-chromosome results have been re-calibrated and this will change with whom some of those tested match and don't match. Even for those who still match the same individuals, the probabilities of how many generations ago that match occurred are likely to have changed.

Within our Dowell DNA Project we have triangulated 111 marker Y-chromosome results of living descendants of three of the sons of my 6th great-grandfather. Through this process we have been able to reconstruct what the 111 marker DNA signature would have been of Philip Dowell, Sr. who died in 1733. The recent changes in the FTDNA database do not change our overall result. However, they reduce the mutations of some of us who participated  in this process. The chart immediately shows our descendancy from Philip:


Before the re-calibration of the database, the living descendants, who are represented by the lowest boxes in each column, had a combined total of 10 mutations from Philip, Sr. Today they are shown as having 8. From left to right: the descendant of Philip, Jr., still has 2 mutations over the generations. The descendant of John dropped from 6 to 5 mutations. The two of the descendants of Peter, Sr., previously were shown as have 1 mutation each and the third was shown as having no mutations. The revised results show two with no mutations and one still having a single mutation over the generations. Are these revisions significant? They don't change the previously predicted DNA signature of Philip, Sr. However, in borderline cases, it could change whether two men were shown as matches or did not ever show up on each others results pages.

Other 111 marker matches with different surnames, who were previously shown as having a genetic distance of 9 or 10, now show up as having a genetic distance of 5. No new men joined this cluster as a result of the changes in reporting.

The events of the last few days make one think, "Everything I knew about genetic genealogy has changed." But then we haven't heard anything from Ancestry lately. I wonder how long it will take them to try to get back in the spotlight?


Tuesday, December 11, 2012

$99 Autosomal DNA Test from 23andMe


The following press release from 23andMe has the potential to drastically change the economics of the autosomal DNA market. The company is announcing what it says is a permanent price drop of its combined genealogy and health factors test to $99. This is the result of new funding and the launching of an ambitious plan to expand its current database of testers from 150,000 to 1,000,000. At this price many will find the price to be attractive for many family members. Autosomal testing for genealogical purposes is helpful for the last few generations to find close cousins but does not have the power to trace distant paternal and maternal lines that Y-chromosome and mitochondrial DNA can track. 

The health related information can be equally valuable. My wife and I now are patients of the Vanderbilt University Heath Clinics. Vanderbilt is beginning an ambitious plan to match patient records with DNA information that will PREDICT how those patients will react to drug therapy before the drugs are prescribed. Both of us had tested at 23andMe three years ago and were given the same information at that time as Vanderbilt confirmed this past summer.

It remains to be seen how soon 23andMe will be able to reach its ambitious goal of 1,000,000 tested. However, the economics of the marketplace for direct to consumer DNA testing just changed. I hope the major databases will remain economically viable. Need I suggest that you may want to reevaluate what you were planning to give family members for Christmas?

The full text of the press release is below:

  

23andMe Raises More Than $50 Million in New Financing
Company Sets Growth Goal Of One Million Customers, Reduces Price to $99 from $299
MOUNTAIN VIEW, Calif. – December 11, 2012 – 23andMe, Inc., the leading personal genetics company, today announced it has raised more than $50 million in a Series D financing. Participants in the financing include Yuri Milner, a new investor, as well as existing investors Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. This investment will help the company achieve its growth goal of one million customers.
The Power of One Million PeopleExpanding the company’s ability to reach and serve one million individuals supports 23andMe’s goal to revolutionize health and wellness. It also will accelerate 23andMe’s ability to create a powerful platform that enables researchers around the globe to make meaningful discoveries significantly faster than is currently possible. With this expansion, 23andMe, which currently has more than 180,000 customers, will aim to:
  • Enable groundbreaking research by creating an exponentially larger collective of actively engaged, genotyped individuals;
  • Help accelerate development of new treatments;
  • Improve understanding of wellness and disease prevention; and
  • Broaden access for people seeking to manage their health and well-being through direct access and greater understanding of their own genetic data.
“A community of one million actively engaged individuals will be transformational for research. A community of this magnitude will improve researchers’ ability to quickly answer questions about genetic function and the role of environmental factors. In addition, it will enable researchers to understand medication efficacy and side effects, in both medications that exist today and medications are that are in development,” Wojcicki added.
Broadening Access: Lowering Price to $99
The Series D investment, combined with rapidly decreasing costs associated with genetic testing technologies, enables 23andMe to reduce the price of its Personal Genome Service to $99, effective immediately. The company will continue to evaluate optimal pricing strategies.
The investment also enables 23andMe to expand the necessary infrastructure to support growth in its research and operational capabilities, including product development, genetic research, software development, recruitment and marketing.

About 23andMe
23andMe, Inc. is the leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company's Personal Genome Service® enables individuals to gain deeper insights into their ancestry and inherited traits. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science. More information is available at www.23andme.com